Genetics Graduate Program, Department of Anatomy and Cell Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
MAbs. 2009 Sep-Oct;1(5):422-31. doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15.
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.
戈利木单抗是一种人抗 TNFalpha IgG1kappa 单克隆抗体，于 2009 年 4 月在美国和加拿大获批用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎，目前正在欧盟进行这些适应证的监管审查。该产品由 Centocor 和 Janssen Pharmaceutical KK（强生的子公司）与先灵葆雅和武田制药合作开发。戈利木单抗在市场上面临众多蛋白治疗竞争对手，但作为首个患者可自行给药、每月一次给药的抗 TNFalpha 药物，它可能是患者的一个有吸引力的选择。
